How Linagliptin, Dapagliflozin and Metformin Help Manage Type 2 Diabetes

LINALIGLIP DAPAMET is a three-drug fixed-dose combination tablet for adults with type 2 diabetes mellitus. It brings together three antidiabetic medicines from three different classes:

• Linagliptin 5 mg: a DPP-4 inhibitor
• Dapagliflozin 10 mg: an SGLT2 inhibitor
• Metformin Hydrochloride SR (500 mg or 1000 mg): a biguanide in sustained release form

The product is referred to in two metformin strengths: linagliptin 5 mg + dapagliflozin 10 mg + metformin SR 500 mg, and linagliptin 5 mg + dapagliflozin 10 mg + metformin SR 1000 mg. 

This is a prescription-only medicine. A registered doctor decides whether it is right for you and which strength to use.

Indications: What Is Linagliptin, Dapagliflozin and Metformin Used For?

The combination is intended to improve blood sugar control in adults with type 2 diabetes, together with a healthy diet and regular physical activity. A doctor may consider it when:

1. HbA1c remains above target despite treatment with metformin alone or a two-drug combination.
2. The patient already takes linagliptin, dapagliflozin and metformin as separate tablets and wants a simpler routine.
3. A regimen with a low risk of hypoglycaemia is preferred, since none of the three drugs causes low sugar by itself.
4. Kidney function needs to be taken into account, as linagliptin is cleared mainly through the bile and gut and usually does not need dose adjustment for reduced kidney function.

It is not meant for type 1 diabetes or diabetic ketoacidosis. The choice of metformin strength depends on blood sugar levels, kidney function, stomach tolerance and overall health.

How the Three Medicines Work Together

Type 2 diabetes involves several problems at once: the liver releases too much glucose, tissues respond poorly to insulin, the pancreas releases insulin inadequately after meals, glucagon stays high, and the kidneys keep reabsorbing glucose. This combination targets several of these defects together.

Linagliptin 5 mg: the DPP-4 inhibitor

Linagliptin blocks the enzyme dipeptidyl peptidase-4 (DPP-4), which normally breaks down the incretin hormones GLP-1 and GIP. With more active incretins, the pancreas releases insulin in response to rising glucose and reduces glucagon. This action depends on blood sugar levels, so the risk of hypoglycaemia is low. Linagliptin 5 mg is taken once daily and is notable for its mostly non-renal elimination.

Dapagliflozin 10 mg: the SGLT2 inhibitor

Dapagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2) in the kidney tubules. This protein normally returns filtered glucose to the blood. When it is blocked, excess glucose leaves the body in urine. The effect is independent of insulin, so it continues to work even when pancreatic function has declined. Dapagliflozin is also associated with modest weight loss and a small reduction in blood pressure.

Metformin Hydrochloride SR: the biguanide

Metformin has been the first-line drug for type 2 diabetes for decades. It lowers glucose production in the liver and improves insulin sensitivity in muscle and fat. The sustained release form releases the drug gradually, which commonly improves stomach tolerance compared with immediate release tablets.

The combined effect

• Metformin addresses insulin resistance and liver glucose output.
• Linagliptin supports meal-time insulin release and lowers glucagon.
• Dapagliflozin removes glucose through the kidneys.

Three separate pathways, one tablet.

Key Benefits of LINALIGLIP DAPAMET

1. Stronger glucose lowering through three mechanisms: Combining drugs with different actions generally lowers HbA1c more than increasing the dose of one drug.

2. Low risk of hypoglycaemia: None of the three drugs triggers insulin release regardless of glucose level, so low sugar episodes are uncommon unless insulin or a sulfonylurea is added.

3. Possible weight and blood pressure benefit: Dapagliflozin may cause modest weight loss and a small fall in systolic blood pressure. Linagliptin and metformin are generally weight-neutral.

4. Kidney-friendly DPP-4 choice: Linagliptin generally needs no dose change in kidney impairment, though metformin and dapagliflozin both have kidney-related limits, so overall kidney function must still be checked.

5. Heart and kidney relevance: Dapagliflozin has been studied in large trials in heart failure and chronic kidney disease. Linagliptin has cardiovascular and kidney safety data from dedicated trials. Whether wider benefits apply to you is a decision for your doctor.

6. Fewer tablets: One tablet in place of three reduces pill burden and may help people stay consistent with treatment.

Efficacy and Clinical Evidence

The evidence below relates to the individual ingredients and to the combination approach. Brand-specific results should always be confirmed against the approved prescribing information.

Linagliptin 5 mg

• In placebo-controlled trials, linagliptin 5 mg lowered HbA1c by roughly 0.5% to 0.7% when used alone or added to other therapy, with weight neutrality and a low rate of hypoglycaemia.
• CARMELINA (about 6,900 patients with type 2 diabetes and high cardiovascular or kidney risk) showed that linagliptin did not increase major cardiovascular events or worsen kidney outcomes compared with placebo.
• CAROLINA compared linagliptin with glimepiride in people with type 2 diabetes at cardiovascular risk. It showed cardiovascular safety similar to glimepiride, with fewer hypoglycaemic events and no weight gain.

Dapagliflozin 10 mg

• In randomised trials, dapagliflozin 10 mg lowered HbA1c by roughly 0.5% to 0.8% versus placebo when added to other agents, with weight reductions of around 2 to 3 kg.
• DECLARE-TIMI 58 studied more than 17,000 patients with type 2 diabetes and found a lower rate of hospitalisation for heart failure.
• DAPA-HF and DAPA-CKD showed benefits in heart failure with reduced ejection fraction and in chronic kidney disease respectively, including patients without diabetes.
• Its glucose-lowering effect weakens as eGFR falls.

Metformin Hydrochloride

• UKPDS 34 showed that metformin reduced diabetes-related complications and mortality in overweight patients with newly diagnosed type 2 diabetes.
• Metformin typically lowers HbA1c by about 1.0% to 1.5%, is weight-neutral and has a long safety record.

Combination evidence

Trials of an SGLT2 inhibitor added to a DPP-4 inhibitor plus metformin have shown further improvements in HbA1c and body weight compared with placebo, with safety consistent with the individual drugs. Published trials of this exact fixed-dose triple tablet are more limited than evidence for the separate components, so the clinical case rests largely on the evidence for each drug and the complementary mechanisms. Individual response varies.

Dosage and How to Take It

• Take LINALIGLIP DAPAMET exactly as your doctor prescribes, usually once daily with a meal.
• Swallow the tablet whole with water. Do not crush, break or chew sustained release tablets.
• Do not switch between the 500 mg and 1000 mg metformin strengths on your own.
• If you miss a dose, take it when you remember unless the next dose is near. Never take two doses together.
• Stay well hydrated throughout treatment.

Who Should Not Take It

Avoid this medicine if you:

• Are allergic to linagliptin, dapagliflozin, metformin or any other ingredient.
• Have type 1 diabetes or have had diabetic ketoacidosis.
• Have severe kidney impairment or are on dialysis.
• Have significant liver disease.
• Have conditions that raise the risk of lactic acidosis, such as severe infection, dehydration, or heart or respiratory failure.

Precautions and Warnings

Kidney function: Kidney tests are needed before starting and regularly afterward. Metformin is stopped at very low eGFR, and dapagliflozin’s glucose-lowering effect declines as kidney function falls.

Lactic acidosis: Rare but serious with metformin. Warning signs include unusual muscle pain, rapid breathing, severe tiredness, stomach pain and feeling cold. Seek emergency care.

Ketoacidosis: SGLT2 inhibitors can cause diabetic ketoacidosis, sometimes with near-normal blood sugar. Nausea, vomiting, stomach pain, fast breathing and unusual tiredness need urgent attention. Tell your doctor before surgery, prolonged fasting or serious illness, as the medicine may need to be paused.

Genital and urinary infections: Glucose in urine can encourage genital yeast infections and urinary tract infections. A rare but serious infection called Fournier’s gangrene has been reported with SGLT2 inhibitors. Pain, redness or swelling in the genital area needs urgent review.

Pancreatitis: Severe, persistent stomach pain, sometimes spreading to the back, should be reported immediately, as DPP-4 inhibitors have been associated with pancreatitis.

Joint pain and skin reactions: Severe joint pain and blistering skin conditions such as bullous pemphigoid have been reported with DPP-4 inhibitors. Report them to your doctor.

Dehydration and low blood pressure: Dapagliflozin has a mild diuretic effect. Be careful in hot weather and during vomiting or diarrhoea.

Contrast dye and surgery: Metformin may need to be paused around iodinated contrast imaging and surgery.

Vitamin B12: Long-term metformin use can lower vitamin B12, so periodic checks may be advised.

Alcohol: Heavy drinking raises the risk of lactic acidosis, ketoacidosis and low blood sugar.

Possible Side Effects

Common: nausea, diarrhoea, stomach discomfort, headache, increased urination, genital itching or yeast infection, urinary tract infection, runny nose or sore throat.

Serious but less common: lactic acidosis, ketoacidosis, pancreatitis, severe genital infection, severe skin reactions, and signs of allergy such as swelling of the face or throat, rash or difficulty breathing. Seek emergency help if these occur.

Stomach side effects from metformin often ease over time, and taking the tablet with food helps.

Lifestyle Tips During Treatment

• Follow a balanced, portion-controlled diet and limit sugary foods and drinks.
• Stay active. About 150 minutes of brisk activity a week is a common target if your doctor agrees.
• Monitor blood sugar and HbA1c as advised.
• Maintain genital hygiene and drink enough water.
• Do not stop the medicine on your own, even when readings improve.

How It Compares with Other Combinations

You may see dual combinations such as teneligliptin 20 mg and metformin hydrochloride 500 mg, which pair a DPP-4 inhibitor with metformin. LINALIGLIP DAPAMET adds dapagliflozin as a third mechanism, which can help when two drugs are not enough or when weight, blood pressure, or heart and kidney considerations matter. The best option depends on the individual, which is why a doctor’s assessment is essential.

Storage

Store below 30°C in a cool, dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiry date.

Frequently Asked Questions

1. What is LINALIGLIP DAPAMET used for?
LINALIGLIP DAPAMET is used with diet and exercise to control blood sugar in adults with type 2 diabetes. It contains linagliptin, dapagliflozin and metformin.

2. What is linagliptin 5 mg used for?
Linagliptin 5 mg helps the pancreas release insulin after meals and lowers glucagon, which reduces blood sugar in type 2 diabetes.

3. What is dapagliflozin 10 mg used for?
Dapagliflozin 10 mg lowers blood sugar by making the kidneys pass extra glucose in urine. Doctors also use it in some patients with heart failure or chronic kidney disease.

4. What is metformin hydrochloride tablet used for?
Metformin tablets are a first-line treatment for type 2 diabetes. They reduce glucose production in the liver and improve insulin sensitivity.

5. What are the uses of metformin hydrochloride 1000 mg?
It is a higher-strength metformin dose used for type 2 diabetes when a doctor judges it appropriate based on sugar levels, tolerance and kidney function.

6. How do linagliptin, dapagliflozin and metformin work together?
Metformin lowers liver glucose output, linagliptin boosts meal-time insulin, and dapagliflozin removes glucose through urine. Together they cover three different problems in type 2 diabetes.

7. What is the difference between metformin 500 mg and 1000 mg in this combination?
Linagliptin 5 mg and dapagliflozin 10 mg stay the same. Only the metformin SR amount changes, and your doctor chooses it.

8. Does it cause weight loss?
Some people lose a little weight, mainly from dapagliflozin. It is not a weight-loss drug, and results vary.

9. Does it cause low blood sugar?
The risk is low on its own, but it rises if you also take insulin or a sulfonylurea, skip meals or drink heavily.

10. When should I take it?
Usually once daily with a meal, as prescribed. Swallow it whole without crushing or chewing.

11. What are the common side effects?
Nausea, diarrhoea, stomach upset, headache, increased urination, and genital or urinary infections are among the most common.

12. Who should avoid linagliptin, dapagliflozin and metformin?
People with type 1 diabetes, ketoacidosis, severe kidney or liver disease, or an allergy to any ingredient should avoid it.

13. Is it safe for kidney patients?
It depends on kidney function. Metformin and dapagliflozin both have eGFR-related limits, so your doctor will check kidney tests first.

14. Is linagliptin safe in kidney disease?
Linagliptin usually needs no dose change for kidney impairment, but the other two drugs in this combination do have limits.

15. What is the linagliptin 5 mg price?
Price varies by brand, pack and pharmacy. Check the MRP on the pack or ask your pharmacist.

Conclusion

LINALIGLIP DAPAMET brings together linagliptin 5 mg, dapagliflozin 10 mg and metformin hydrochloride SR in one tablet for adults with type 2 diabetes. By acting on the pancreas, kidneys and liver together, it can improve glycaemic control with a low hypoglycaemia risk, offer possible modest benefits for weight and blood pressure, and simplify the daily routine. It also carries real risks, including lactic acidosis, ketoacidosis, genital and urinary infections, dehydration and pancreatitis, so regular monitoring and open communication with your doctor are essential. This is a prescription medicine and should only be started, adjusted or stopped under medical supervision.

For Further More Information:  

Mail Us: contact@sterispharma.com or info@sterispharma.com

Call Now: +918824175417, +919982524671

Buy Now